PARSIPPANY, N.J., Nov. 21, 2011 /PRNewswire/ -- Switzerland-based Ferring Pharmaceuticals today announced the purchase of a 25-acre site at 100 Interpace Parkway in Parsippany, N.J. The new facility will house a state-of-the art, expanded U.S. Operations Center. The expansion is expected to generate jobs in the New Jersey area, countering recent trends in the pharmaceutical industry.
The U.S. Operations Center will be a fully integrated pharmaceutical facility that will house management, administration and support, commercial operations, manufacturing and product development. It will include a state-of-the-art manufacturing suite, next-generation product development laboratories, a fully equipped education and training conference center, and administrative offices.
"As a private company, Ferring has a long term orientation, as well as a commitment to follow the science to benefit patients. This new facility underscores our long-term commitment to the U.S. market, as well as the State of New Jersey," said Aaron Graff, President and Chief Operating Officer of Ferring Pharmaceuticals, Inc.
"Together with our Global Research Center in San Diego, this symbolizes our focus on accelerating Ferring growth in the United States. The local community has continuously expressed support for our endeavors, and we are so pleased to expand our operations in an area with such a large base of talented, highly trained pharmaceutical professionals."
The Switzerland-based company has experienced consistent double-digit growth in the U.S. and has approximately 600 U.S. employees. Globally Ferring has nearly 5,000 employees with operations in more than 45 countries.
About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, global pharmaceutical company. Ferring Pharmaceuticals offers a line of products in the U.S. market. They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR® (menotropins for injection, USP) and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, LYSTEDA® (tranexamic acid tablets), FIRMAGON® (degarelix for injection), and EUFLEXXA® (1% sodium hyaluronate).
Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.
All registered trademarks above are owned by Ferring B.V.
|SOURCE Ferring Pharmaceuticals Inc.|
Copyright©2010 PR Newswire.
All rights reserved